- Details
- Yair Lotan discusses the STRATA trial, a multicenter study comparing the Cxbladder Triage test to traditional cystoscopy in patients with microhematuria. This trial explores whether a high negative predictive value biomarker test can safely reduce the number of unnecessary cystoscopies in low-risk patients. Microhematuria, a common condition affecting millions annually in the U.S., is frequently o...
|
- Details
- Ashish Kamat hosts a discussion with Roger Li and Trinity Bivalacqua on the CORE-001 study evaluating cretostimogene grenadenorepvec and pembrolizumab for BCG-unresponsive CIS. Dr. Li highlights the 83% complete response rate at any time, 57.1% at 12 months, and 54.3% at 24 months, noting the therapy's durability and lack of progression to muscle-invasive or metastatic disease. The combination the...
|
- Details
- Sam Chang interviews Edward Messing about his research on using apalutamide for non-muscle invasive bladder cancer. Dr. Messing discusses a trial aiming to explore whether antiandrogens like apalutamide can prevent bladder cancer recurrence, given its higher prevalence in men. This molecular proof-of-principle study, sponsored by the National Cancer Institute, focuses on the role of androgen recep...
|
- Details
- Sam Chang interviews Karim Chamie about pivotal clinical trials in urothelial carcinoma presented at AUA 2024. Dr. Chamie discusses the MoonRISe-1 trial, a Phase III study on TAR-210 (an erdafitinib intravesical delivery system) for intermediate-risk non-muscle-invasive bladder cancer, highlighting its innovative approach and potential to change the treatment landscape. He also reviews the SunRISe...
|
- Details
- Sam Chang interviews Neal Shore about the KEYNOTE-676 trial. This global study evaluates the efficacy of combining Pembrolizumab with BCG induction and maintenance in patients who had previously received an induction course of BCG without maintenance. Dr. Shore discusses the study’s aim to enhance the effectiveness of BCG therapy in non-muscle invasive bladder cancer (NMIBC) by adding a checkpoint...
|
- Details
- Sam Chang interviews Woodson Smelser to discuss takeaways from the AUA Annual Meeting in urothelial carcinoma, highlighting the rapid advancements in non-muscle invasive bladder cancer therapies. He emphasizes the importance of new FDA-approved agents like Pembrolizumab, Nadofaragene, and Nogapendekin. Dr. Smelser also reviews clinical trials, such as the TAR-200 device and the CG0070 adenovirus....
|
- Details
- Ashish Kamat hosts a discussion with Matt Galsky and Neal Shore on the latest advancements in bladder cancer treatment, focusing on immunotherapy for advanced bladder cancer and the associated survival benefits. He emphasizes the importance of recognizing and managing immune-related toxicities. Dr. Shore discusses the application of immunotherapy in earlier stages of disease, mentioning pembrolizu...
|
- Details
- Ashish Kamat engages with Kamal Pohar and Kelly Bree on bladder cancer surveillance. They discuss the ongoing debate about the utility of various urinary markers in monitoring bladder cancer. Dr. Pohar mentions his reliance on cytology, while Dr. Bree adds that she uses cytology and occasionally UroVysion FISH for atypical cases, and also blue light cystoscopy despite its challenges. They both hig...
|
- Details
- Ashish Kamat hosts Sima Porten and Roger Li to discuss the management of BCG-unresponsive bladder cancer. They emphasize personalized patient care, starting by understanding patients' goals and risk tolerance. Dr. Porten highlights the importance of discussing radical cystectomy as the gold standard while also considering bladder-preserving treatments depending on the patient's disease characteris...
|
- Details
- Ashish Kamat welcomes Petros Grivas to discuss the current state and future prospects of treating invasive bladder cancer with neoadjuvant chemotherapy or immunotherapy followed by local therapy. Dr. Grivas emphasizes the current standard of care involving neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy or chemoradiation. He highlights promising clinical trials, such as RET...
|
